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The interaction of the cell-contact proteins VASP and vinculin is
regulated by phosphatidylinositol-4,5-bisphosphate 
Stefan Hüttelmaier*, Oleg Mayboroda†, Birgit Harbeck*, Thomas Jarchau‡,
Brigitte M. Jockusch* and Manfred Rüdiger*
Background: Focal adhesion sites are cell–matrix contacts that are regulated
by phosphatidylinositol-4,5-bisphosphate (PIP2)-dependent pathways. Vinculin
is a major structural component of these sites and is thought to be engaged in
multiple ligand interactions at the cytoplasmic face of these contacts.
Cytoplasmic vinculin is considered to be inactive due to its closed conformation
involving intramolecular head–tail interactions. Recently, the vasodilator-
stimulated phosphoprotein (VASP), a substrate of cyclic AMP-dependent or
cyclic GMP-dependent kinases and a component of focal adhesion sites, was
shown to bind to vinculin. 
Results: VASP–vinculin complexes could be immunoprecipitated from cell
lysates and, using immunofluorescence, both proteins were found to colocalize
in nascent focal adhesions. Consistent with the view that vinculin must be
activated at these sites, we found that PIP2, levels of which are elevated during
the early stages of adhesion, bound to two discrete regions in the vinculin tail,
disrupting the intramolecular head–tail interaction and inducing vinculin
oligomerization. Vinculin–VASP complex formation was greatly enhanced by PIP2
and both the EVH1 and EVH2 domains of VASP participated in vinculin binding.
Conclusions: Focal contact assembly involves interaction between VASP and
vinculin, which is enhanced by PIP2-induced vinculin activation and
oligomerization. Given that vinculin and VASP both bind to F-actin,
vinculin–VASP complexes might bundle the distal ends of actin filaments in
focal contacts. We propose that PIP2-dependent signalling modulates
microfilament organization at cellular adhesion sites by regulating
vinculin–VASP complexes.
Background
Vasodilator-stimulated phosphoprotein (VASP), a protein
of 380 amino acids, is a substrate of cyclic AMP-dependent
and cyclic GMP-dependent protein kinases. It is found in a
variety of tissues and is associated with focal adhesions,
microfilaments, cell–cell contacts and the lamellipodia of
cultured cells [1–4]. Recent data suggest that VASP has an
important role in the regulated organization of microfila-
ments at membrane-attachment sites in general, including
the interface between the bacterium Listeria monocytogenes
and the actin comet tail recruited by this intracellular para-
site from the host’s actin supply [5,6]. VASP has been
shown to be a multi-ligand protein that binds directly to fil-
amentous actin [2], profilin [7], the Listeria surface protein
ActA [6], zyxin [3] and vinculin [8,9]. Like zyxin [10,11],
vinculin, a 116 kDa protein, is a major component of cellu-
lar junctions [12,13]. Assembly, maintenance and regula-
tion of adherens junctions and thus tissue integrity depend
critically on vinculin levels [14–16]. The overall domain
structures of vinculin and its ligand VASP are depicted in
Figure 1. The binding of VASP to vinculin, ActA and zyxin
has been attributed to proline-rich sequences, in particular
to an FPPPP (FP4; in single-letter amino-acid code) motif
present in all three of these ligands [8,9,17,18]. Whereas
binding of VASP and related proteins [19] to zyxin and
ActA is of rather high affinity, binding to vinculin was
found to be comparatively weak. This was explained by
the fact that zyxin and ActA contain tandem repeats of the
FP4 motif, whereas vinculin contains only a single copy [9].
In addition, VASP–vinculin complex formation may be
influenced by an intramolecular interaction of the vinculin
head and tail domains that controls the activity of ligand-
binding sites [20], as already demonstrated for vinculin
binding to F-actin, talin, α-actinin and acidic phospho-
lipids [21–26]. Recently, it has been postulated that this
intramolecular interaction and thus ligand binding of vin-
culin might be regulated by binding of the signalling mole-
cule phosphatidylinositol-4,5-bisphosphate (PIP2) and
possibly also by serine/threonine phosphorylation [27–30]. 
Here, we show that both VASP and vinculin concentrate in
focal contacts during cell spreading. For several mammalian
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cell types, the contact between integrins and the extracel-
lular matrix, which is established during spreading, has
been shown to increase synthesis of PIP2, resulting in ele-
vated PIP2 levels [31,32]. We demonstrate that PIP2 acti-
vates vinculin by interfering with its head–tail association,
favouring its oligomerization. We have characterized sites
in the vinculin tail that are involved in PIP2 binding and
show that PIP2 binding greatly enhances formation of the
VASP–vinculin complex, probably stimulated by vinculin
oligomerization. On the basis of these data, we propose a
model of how these molecules might be involved in the
organization of the actin cytoskeleton during the assembly
of cell–matrix attachment sites.
Results
Vinculin and VASP form complexes in cells and colocalize
in nascent focal contacts 
VASP, like vinculin, is a prominent component of cellular
adherens junctions [2,7,13]. Both VASP and vinculin colo-
calize in fully spread, stationary epithelial and fibroblastic
cells, suggesting that the direct interaction of both pro-
teins shown in vitro [8,9] is also relevant in living cells. To
detect vinculin–VASP complexes under physiological con-
ditions, we used chemical cross-linking of proteins in cells,
before solubilizing protein aggregates in a lysis buffer.
HeLa cells were treated with the membrane-permeable
cross-linker dithiobis-succinimidylpropionate (DSP), and
lysed 30 minutes later. The extracts were incubated with
either anti-vinculin or anti-VASP antibodies, and both sets
of immunoprecipitates were analyzed in immunoblots
with antibodies against both proteins. As seen in Figure 2,
the immunoprecipitates obtained with either anti-vinculin
or anti-VASP antibodies contained both vinculin and
VASP. Thus, these results suggest the presence of vin-
culin–VASP complexes in living cells. 
Both VASP and vinculin are recruited at an early stage
during the formation of focal contacts in spreading cells.
HeLa cells, fixed and processed for detection of VASP
and vinculin by immunofluorescence 0.5–1 hours after
seeding, showed peripheral lamellae and multiple small
focal contacts. As seen in Figure 3, both VASP and vin-
culin were concentrated in the small peripheral focal con-
tacts formed during cell spreading 1 hour after seeding.
Identical results were also obtained with cells 30 minutes
after seeding and with cells transfected with a green fluo-
rescent protein (GFP)–VASP fusion construct (data not
shown). Hence, these observations indicate that vinculin
and VASP are already found in a complex in living cells
when PIP2 levels are elevated [31,32].
PIP2 disrupts head–tail interactions and induces tail
oligomerization in vinculin
Current evidence suggests that cytoplasmic vinculin is
inactive in ligand binding, because it has a closed confor-
mation, but becomes activated at adhesion sites [25].
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Figure 1
Schematic organization of VASP and vinculin.
These illustrations are based on references
given in the text. (a) VASP can be divided into
three functionally distinct domains: EVH1, the
proline-rich central domain and EVH2, each
delineated by the labelled amino-acid
residues. The location of the binding sites for
identified ligands are indicated. The F-actin-
binding region has not yet been attributed to
one of these domains. VASP exists as a
tetramer, but structural details have not been
elucidated. (b) Vinculin comprises a large,
compact amino-terminal head and a rod-like
tail that are connected by a flexible, proline-
rich hinge region. The FP4 motif is located
within the proline-rich region. A V8 cleavage
site severs the larger part of the hinge region
plus the tail from the head. Binding sites for
various ligands of the head, hinge and tail
domains are indicated. 
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Activation of vinculin may involve the release of its
head–tail interaction by PIP2 [27,29]. To characterize
further the effect of PIP2 on vinculin head–tail interac-
tions and to characterize the PIP2-binding site in vinculin,
we performed cross-linking experiments with isolated
head (amino-acid residues 1–850) and tail (amino-acid
residues 851–1066 and 858–1066) fragments and moni-
tored the effect with antibodies specific for either the vin-
culin head or tail regions. In the absence of PIP2,
mixtures of isolated vinculin heads and tails (molar ratios
1:1) were rapidly and efficiently cross-linked by 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide (EDC), as
demonstrated by the fact that, after cross-linking, the tail-
specific antibody recognized a target of the same molecu-
lar weight as intact vinculin (Figure 4). The proportion of
cross-linked fragments increased with time over
90 minutes (Figure 4). In contrast, in the presence of 100-
fold molar excess PIP2, the tail fragments showed no such
shift. Instead, a new antibody-reactive band appeared at
the calculated position of the vinculin-tail dimer and, at
later time points, increasing amounts of oligomeric com-
plexes composed only of vinculin tails were seen, whereas
the monomeric tail species had disappeared (Figure 4).
Hence, PIP2 efficiently inhibits the head–tail interaction of
vinculin and induces oligomerization of the tail fragments.
The specificity of this effect was studied further. Figure 5
shows the concentration-dependent oligomerization of vin-
culin tail fragments induced by either PIP2 or phos-
phatidylserine (PS), again seen after EDC cross-linking and
monitored with the tail-specific anti-vinculin antibody. At
molar ratios of 1:1 to 1:100 (protein : phospholipid), PIP2
induced the formation of oligomers increasing in size and
quantity, leading to a decrease in the amount of the
monomeric form, whereas PS was much less effective,
yielding no substantial decrease of the monomer pool
(Figure 5). The formation of higher molecular weight vin-
culin–tail oligomers (trimers to pentamers) was most effi-
cient within the PIP2 molar-excess range of 1:10 to 1:20,
whereas above this value, still more dimers were formed
but the formation of larger oligomers was seen to decline.
Such an effect was not seen with PS over the same concen-
tration range. Analogous curves showing optimum protein
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Figure 2
Complex formation between VASP and vinculin in cells, as detected by
immunoprecipitation after in situ cross-linking. HeLa cells either treated
(+) or not treated (–) with DSP were lysed and subjected to
immunoprecipitation (IP) with (a,b) anti-vinculin or (c,d) anti-VASP
antibodies. Both precipitates were analyzed by SDS–PAGE and
immunoblotted with either (a,c) anti-vinculin or (b,d) anti-VASP
antibodies. Immunoblots were developed with either (a,d)
chloronaphthol or (b,c) enhanced chemiluminescence. Note that
VASP–vinculin complexes were detected only after in situ cross-
linking.
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Figure 3
Recruitment of VASP and vinculin to nascent focal contacts in
spreading cells. HeLa cells were fixed 1 h after seeding and double-
stained with antibodies against VASP (red) and vinculin (green). At this
early time point after seeding, the attached cells are still fairly globular,
but at the periphery, protruding lamellae have formed with small,
nascent focal contacts which contain both (a–c) VASP (red) and
(d–f) vinculin (green), as seen in (g–i) the superimposed images
(yellow). (a,b,d,e,g,h) Conventional fluorescence microscope images of
two different cells. (c,f,i) Images obtained by confocal laser scanning
microscopy. The inset shows an enlargement of a nascent focal
contact. Bars represent 10 µm, the insets are magnified 2.5 times.
to phospholipid ratios have been described previously for
PIP2 binding to α-actinin [33]. Similar results were obtained
with full-length vinculin and with the PIP2-binding fusion
proteins described in Figure 6 (data not shown).
To determine whether other phospholipid components of
plasma membranes might influence the effect of PIP2 on
vinculin, we analyzed PIP2-induced vinculin oligomeriza-
tion in the presence of phosphatidylcholine (PC). Cross-
linking experiments and subsequent analysis of the
samples by SDS–PAGE, analogous to the experiments
described in Figure 4, showed that the stimulation of
oligomer formation was completely inhibited by the pres-
ence of 10% PC in the lipid mixture (data not shown).
Thus, in this system, we observed activation of vinculin
only upon PIP2 binding.
PIP2 binds in the same region as actin in the vinculin tail
We next identified PIP2-binding regions within the vin-
culin tail. Various vinculin tail fragments, produced as
maltose-binding protein (MBP) fusion proteins in
Escherichia coli, full-length purified vinculin and the proteo-
lytically cleaved vinculin tail were each tested for PIP2
binding by immunoprecipitation with anti-PIP2 antibody.
As seen in Figure 6, a small amount of protein precipitated
without PIP2 due to non-specific binding to protein-
A–Sepharose. In the presence of PIP2, however, vinculin
and its tail fragment, and various recombinant fusion pro-
teins containing tail sequences, were efficiently precipi-
tated by the PIP2 antibody. MBP alone did not sediment,
in either the presence or the absence of PIP2. The data
suggest that two separate sequence stretches of vinculin
(amino acids 893–985 and amino acids 1016–1066) are
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Figure 4
The effect of PIP2 on head–tail interaction in
vinculin. Head and tail fragments of vinculin
were cross-linked with EDC in the absence
(–) or presence (+) of a 100-fold molar
excess of PIP2 for between 1 and 90 min as
indicated. Vinculin tail fragments (VT), tail
dimers (VT2), full-length vinculin (V) and
vinculin tail oligomers (oligoVT) were identified
with a vinculin-tail-specific antibody (anti-VT;
left panel), and vinculin head (VH) and full-
length vinculin (V) were detected with a
vinculin-head-specific antibody (anti-VH; right
panel). C indicates control sample without the
cross-linker. After 30 min all vinculin tail
monomers have been cross-linked in the
presence of PIP2.
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Figure 5
The effect of PIP2 and phosphatidylserine
(PS) on vinculin oligomerization. Vinculin tail
fragments were cross-linked by EDC in the
presence of increasing amounts (0–100-fold
molar excess) of either (a) PIP2 or (b) PS.
Oligomerization, indicated by the appearance
of cross-linked dimers and oligomers, was
followed with the vinculin-tail-specific
antibody, and was more efficient in the
presence of PIP2 compared with PS, showing
an optimum at a 10–20-fold excess. PL
indicates phospholipid; EDC, cross-linker. The
numbers refer to the molar excess of the
phospholipid with respect to protein. The
calculated positions for vinculin tail monomers
(VT), tail dimers, trimers, tetramers and
pentamers are indicated on the right.
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involved in the binding of PIP2 to the tail domain. These
are the same regions that are involved in the oligomeriza-
tion of vinculin and in its binding to F-actin [26,34].
The interaction of VASP and vinculin is enhanced by PIP2
binding to vinculin
Previous studies have identified VASP as a ligand for the
proline-rich hinge in vinculin and suggested that VASP
binds to the FP4 motif (amino acids 842–846) within this
region, which is flanked by additional prolines and acidic
amino acids [8,9,18]. Encouraged by findings that several
ligand interactions of vinculin are regulated by acidic
phospholipids [27,29], we analyzed the influence of PIP2
on the interaction of vinculin and VASP by chemical cross-
linking (Figure 7). Equimolar amounts of both proteins
were incubated in the presence or absence of PIP2 and
cross-linked with the zero-length cross-linker EDC. Reac-
tions were stopped by boiling in SDS–PAGE sample
buffer and the samples were analyzed by immunoblotting,
using antibodies against vinculin (Figure 7a) and VASP
(Figure 7b,c). Very little VASP was complexed with vin-
culin in the absence of PIP2 (Figure 7a,b). When PIP2 was
added in a 20-fold molar excess, however, a significant
amount of VASP was detected bound to vinculin at a high
molecular weight position (Figure 7a,b). When PIP2 was at
a 100-fold molar excess over total protein, vinculin was
shifted almost quantitatively to the position of the
oligomers, and a major proportion of VASP comigrated
with it (Figure 7a,b), indicating efficient complex forma-
tion in the presence of PIP2. In control experiments per-
formed without vinculin, VASP did not oligomerize, in
either the absence or the presence of PIP2 (Figure 7c).
Thus, PIP2 specifically enhances the interaction of vin-
culin with VASP. 
Finally, we analyzed the regions in VASP that mediate
complex formation with vinculin. The amino-terminal
domain, a fragment consisting of the EVH1 domain plus
the central proline-rich domain, and the carboxy-terminal
EVH2 domain of VASP (see Figure 1 for explanation)
were each produced as 35S-labelled translation products
and used as probes to assess binding to vinculin in dot
overlay assays as described [34]. All three VASP frag-
ments bound to vinculin, but only when vinculin had
been activated by PIP2 (data not shown). The overlay
assay result for the amino-terminal domain was supported
by cross-linking experiments: a recombinant protein con-
sisting of the amino-terminal 151 amino acids of VASP
(that is, the EVH1 domain with a 38 amino-acid exten-
sion into the central domain; see Figure 1) was used to
characterize the complex formation with vinculin further.
As shown in Figure 8, this fragment could be cross-linked
to vinculin by EDC. In addition, we found that in mix-
tures of both proteins, this amino-terminal fragment
could be coprecipitated with vinculin by anti-vinculin
antibodies (data not shown). Hence, the interaction
between vinculin and VASP might involve both the
EVH1 and EVH2 domains.
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Figure 6
Mapping of PIP2 binding sites within the
vinculin tail. Full-length purified gizzard
vinculin, biotinylated tail fragment, biotinylated
MBP–vinculin tail fusion proteins (MBP–V;
numbers refer to residues of the vinculin
sequence), biotinylated MBP alone (C1) and
MBP–V893–1066 alone (C2) were incubated
with (+) or without (–) PIP2 and
immunoprecipitated with an anti-PIP2
antibody. After SDS–PAGE, biotinylated
samples were blotted and reacted with
avidin–horseradish peroxidase (HRP), and
vinculin was detected by an HRP-coupled
anti-vinculin second antibody, as indicated.
The intact vinculin, the tail fragment and the
fusion proteins used were all precipitated by
an anti-PIP2 antibody, demonstrating that the
vinculin tail sequence contains PIP2-binding
motifs in at least two sequence regions. A
small amount of fusion protein is precipitated
in the absence of both PIP2 and the anti-PIP2
antibody. This is due to non-specific binding
of the protein to protein-A–Sepharose, as
shown for MBP–V893–1066 in C2. The
polypeptide present at a position of about
50 kDa in the vinculin sample is the heavy
chain of the PIP2 antibody labelled by the
second, HRP-coupled antibody.
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Discussion
In this paper, we have characterized the interaction of vin-
culin, a prominent structural component of focal contacts,
and VASP, another constituent of these sites, which is at
the same time a member of a signalling pathway [1]. We
present evidence for the existence of vinculin–VASP com-
plexes in living cells by immunoprecipitation experiments.
The importance of the vinculin–VASP interaction for focal
contact assembly is emphasized by the fact that both
proteins are concentrated in the nascent focal contacts of
spreading cells. Regarding the regions of the VASP
sequence involved in the interaction with vinculin, the
EVH1 domain has been characterized recently as a discrete
functional module in VASP and related proteins, capable of
interacting specifically with FP4 motifs like those present
in vinculin [18]. On the other hand, another study confined
this interaction to a carboxy-terminal region of VASP con-
tained in the EVH2 module [8]. On the basis of our results,
we propose that both EVH1 and EVH2 VASP domains
might contribute to vinculin binding. 
Regarding vinculin, we found that its interaction with
VASP in vitro is greatly influenced by the signalling mole-
cule PIP2, the intracellular level of which is elevated in
several mammalian cell types during cell attachment
[31,32]. PIP2 enhancement of vinculin binding to VASP
and its relative Mena has also been found independently
from our studies by another group (A. Gilmore, L. Petch,
K. Burridge and F. Gertler, unpublished observations,
manuscript in preparation). As we observed that the PIP2
effect is inhibited by PC, one has to assume that, in cells,
vinculin has specific access only to microdomains in the
plasma membrane that are enriched in PIP2 but devoid of
PC, or that PIP2 is specifically delivered to vinculin from
other proteins. Alternatively, the activating effect of PIP2
described in this study is modulated in the living cell by
additional factors, for example by phosphorylation [28].
PIP2 binds to two discrete sequence stretches in the vin-
culin tail, thereby disrupting the head–tail interaction and
inducing oligomerization of vinculin. Electron microscopic
data have already demonstrated the formation of vinculin
oligomers by tail–tail interactions [35], and photo-cross-
linking studies with liposomes have suggested that vin-
culin oligomerizes as the result of its interaction with
acidic phospholipids [36]. The PIP2-binding sites, as iden-
tified in this study, coincide with two regions of predicted
amphipathic helices [37] that are also involved in F-actin
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Figure 7
The effect of PIP2 on complex formation between VASP and vinculin,
as demonstrated by chemical cross-linking. Vinculin and VASP were
treated with EDC without PIP2 (–) or with PIP2 (the fold molar excess
over protein is indicated above the lanes). One half of each aliquot was
analyzed by immunoblotting with either (a) antibodies against the
vinculin tail or (b,c) antibodies against VASP. In (c), VASP was treated
with EDC in the absence of vinculin. Four times as much protein was
loaded onto the gel in (c) compared with (a) and (b). VASP by itself, in
the presence or absence of PIP2, was not cross-linked. The positions
of VASP, vinculin and hetero-oligomers are indicated.
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Figure 8
The interaction of the EVH1 domain of VASP
with vinculin. Immunoblots of mixtures of a
VASP amino-terminal fragment (EVH1 plus
extension, amino-acid residues 1–151) with
vinculin are shown, after cross-linking and
incubation with either (a) an anti-vinculin
antibody or (b,c) an antibody specific for the
EVH1 domain of VASP. EVH1 is detected in
one species of the vinculin oligomers formed
by the cross-linker (b), but it is not detectable
at this position after incubation with the cross-
linker in the absence of vinculin (c). The
double arrowhead indicates the cross-linked
complex in (b).
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binding [26,34]. It is conceivable that F-actin binding is
due, at least in part, to the electrostatic attraction of the
negative charges exposed on the surface of the actin fila-
ments with the positively charged surface of these helices,
although no prediction can be made as to which amino-
acid residues within these regions might be involved in
PIP2 binding. We did not find any motif corresponding to
the specific consensus sequence of basic amino acids iden-
tified in some PIP2-binding proteins of the microfilament
system, such as gelsolin and cofilin [38].
PIP2 enhancement of VASP binding to the FP4-contain-
ing hinge in vinculin, located amino-terminal of the PIP2-
binding tail fragment, might be explained by assuming
that the VASP molecule can bind simultaneously to
several closely spaced FP4 motifs, such as those that
might be exposed in a PIP2-generated vinculin oligomer.
Previous work has shown that in the absence of PIP2,
VASP and its relative Mena bind more strongly to pro-
teins comprising several FP4 motifs, such as zyxin and the
bacterial protein ActA, than to purified vinculin [3,19].
Consistent with these in vitro results are data showing
that in transfected cells the efficiency of VASP recruit-
ment correlates with the number of FP4 motifs in
chimeric proteins comprising various vinculin and ActA
sequences [39]. Furthermore, it has been shown recently
that the proline-rich hinge region of vinculin containing
the FP4 motif is silent in intact vinculin but can be acti-
vated upon removing the vinculin tail sequence [40]. As
discussed above, the EVH2 domain of VASP might also
contribute to the binding of PIP2-activated vinculin.
Hence, PIP2-induced vinculin activation might lead to an
effective recruitment of vinculin oligomers and VASP to
the focal contact site, a process that might be enhanced
by the fact that VASP exists as a tetramer [4]. Tight
bundling of the distal ends of actin filaments at focal
adhesion sites by vinculin tails would then be a conse-
quence of these events. The resulting arrangement of
vinculin, VASP and F-actin is depicted schematically in
Figure 9. In addition, the G-actin-binding protein pro-
filin, which interacts with the proline-rich central region
of VASP [7] and its relatives Mena and Evl [19] might
deliver actin subunits to such complexes for rapid poly-
merization and elongation of the distal ends of actin fila-
ments [9], a process imperative for rapid spreading and
focal adhesion assembly. A large number of microfilament
proteins in focal adhesion sites, such as vinculin, profilin,
talin, α-actinin and gelsolin, bind to and are regulated by
PIP2 (see references within [13,41,42]). Changes in
overall PIP2 levels induced by cell attachment [32], as
well as small, local variations in PIP2 concentrations,
achieved for example by activation of phospholipase Cγ1
[43] or the Rho GTPases [44], might have additive or
even cooperative effects on focal adhesion assembly; this
assembly might be regulated further by phosphorylation
of vinculin [28] and VASP [1].
Our preliminary data suggest that VASP phosphorylation
decreases the efficiency of complex formation with PIP2-
activated vinculin (our unpublished observations); binding
of VASP to isolated proline-rich peptides of vinculin was
not influenced by VASP phosphorylation, however [8]. Of
the three residues in VASP that might be phosphorylated
(Ser157, Ser239 and Thr278 [45]), none is located within
the EVH1 domain that would bind to these peptides, but
two are within the EVH2 domain. Hence, one might
assume that binding to both domains is indeed necessary
for complex formation and regulation. In platelets, VASP
phosphorylation interferes with integrin (glycoprotein
IIb/IIIa) binding to fibrinogen and, consequently, with
platelet aggregation [46]. It remains to be seen whether a
weakening of VASP–vinculin interactions induces such
interfering effects on the activity of integrins in focal
adhesions in general.
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Figure 9
A possible model of the interactions between PIP2, vinculin and VASP
at focal adhesion sites. The cytoplasmic, closed form of vinculin (1) is
opened and thus activated by PIP2 (2) and induced to form oligomers
via its tail domain (3). This model does not preclude other mechanisms
that might additionally regulate vinculin and/or VASP activity, for
example phosphorylation. Concomitantly or subsequently, vinculin
forms complexes with VASP (4) in such a way that several FP4 motifs
exposed in the hinge region of vinculin oligomers bind to VASP. In the
VASP–vinculin complexes, vinculin tails are engaged in bundling the
distal ends of actin filaments (5), close to the plasma membrane. The
vinculin heads and/or VASP can bind to proteins mediating the contact
to integrins (αβ). 
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Material and methods
Preparation of expression constructs
Avian vinculin cDNAs were prepared as described [26]. Specific cDNA
sequences were amplified by PCR using the primers shown in
Table S1 (see Supplementary material). To obtain coding sequences
for proteins comprising MBP and fragments of the vinculin tail, the
cDNAs were cloned into pMAL-c2 (New England Biolabs), using the
restriction sites indicated in Table S1 (see above). The following three
plasmids were obtained, designated according to the amino-acid
residues of the vinculin tail: pMBP–V893–1066, pMBP–V893–985,
pMBP–V1016–1066 (see Table S1). Fragments of cDNAs coding for
the VASP EVH1 domain (residues 1–113), the EVH1 domain plus the
proline-rich region (residues 1–225) and the EVH2 domain (residues
226–380) were amplified from a human VASP cDNA using specific
primers (Table S1) and cloned into pcDNA3 (Invitrogen) to obtain pc-
EVH1, pc-EVH1-PR and pc-EVH2, respectively, for in vitro translation.
All constructs were verified by DNA sequencing.
Expression, purification and modification of recombinant
proteins
E. coli DH5α cells were transformed with the vectors described
above. Expression and purification of the various fusion proteins con-
taining vinculin fragments were essentially as described [34]. VASP
was produced as a recombinant protein with an amino-terminal His tag
in E. coli (BL21(DE3)pREP4). Cells were grown to early log phase in
2 × YT supplemented with 0.2% glycerol, 50 mM potassium phos-
phate, pH 7.2, 5 µg/ml thiamine, 30 µg/ml L-proline, 25 µg/ml
kanamycin and 100 µg/ml ampicillin and induced and further incu-
bated after induction by 1 mM IPTG until early stationary stage. Bacte-
rial sediments were resuspended in lysis buffer (50 mM sodium
phosphate, pH 8.0, 0.5 mM EDTA, 5% glycerol, 50 mM NaCl, 2 µg/ml
leupeptin, 20 U/ml aprotinin, 5 mM benzamidine, 1 mM PMSF, 1 mg/ml
lysozyme), incubated on ice for 30 min and lysed by sonication in the
presence of 5 µg/ml DNAse I and 10 µg/ml RNase. After the addition
of imidazole (final concentration 50 mM, pH 8.0) and Triton X-100 to
0.5%, the lysate was stirred on ice for 20 min. Subsequently, it was
centrifuged (16,500 × g, 10 min), adjusted to 0.3 M NaCl and recen-
trifuged. The clarified extract was then incubated overnight at 4°C with
1 ml Ni–NTA agarose (Qiagen), equilibrated in the same buffer. The
slurry was collected by centrifugation and extensively washed in lysis
buffer (without EDTA and glycerol). The proteins were eluted in
50 mM sodium phosphate, pH 7.0, containing 0.3 M NaCl, 0.1 M
EDTA, and dialyzed against cross-linking buffer (see below). An amino-
terminal VASP fragment, slightly larger than the EVH1 domain (amino-
acid residues 1–151), was expressed as a glutathione-S-transferase
(GST) fusion protein. The GST moeity was removed using thrombin
and the VASP fragment purified and characterized (T. Jarchau et al.,
unpublished). 
Purification of vinculin and proteolytic vinculin fragments
Turkey gizzard vinculin was purified as described [47] using an FPLC
Q–Sepharose column (Pharmacia) instead of the DEAE column. Vin-
culin head and tail fragments were obtained by V8 protease digestion
and purified essentially as described [24].
Preparation of phospholipid micelles
PIP2, PS and PC (Boehringer Mannheim) were dissolved in chloroform
(1 mg/ml), dried under vacuum for 20–30 min and resuspended in LP
buffer (50 mM NaH2PO4, pH 7.2, 0.2 mM EGTA). For the preparation
of mixed lipid micelles, the respective chloroform solutions were com-
bined to yield the desired final concentrations. After sonication
(5 × 1 min), the dispersion was centrifuged at 100,000 × g for 20 min
and the supernatant was used in cross-linking and immunoprecipita-
tion experiments.
Chemical cross-linking
Purified proteins or mixtures of two purified proteins were preincubated
in the presence or absence of lipids at 37°C for 30 min. Cross-linking
of proteins was achieved by incubating a single protein (25–100 pmol,
2.5 µM) or equimolar amounts of proteins (12.5–50 pmol, 1.2–1.4 µM)
with 7 mg/ml N-hydroxysulfosuccinimide (NHS, Pierce) and 1.5 mg/ml
EDC (Pierce) at 30°C for 5 min to 2 h in 50 mM NaH2PO4, pH 7.2,
0.2 mM EGTA. The reactions were stopped by adding SDS–PAGE
sample buffer (375 mM Tris HCl pH 6.8, 2% SDS, 12% glycerol, 0.5 M
β-mercaptoethanol, bromophenol blue). Samples were analyzed by
SDS–PAGE and immunoblotting as described [26].
Protein biotinylation and immunoprecipitation
As some of the recombinant fusion proteins employed in this study
showed an apparent molecular weight after SDS–PAGE similar to the
heavy chain of the antibody used for immunoprecipitation, we used
biotinylated proteins and HRP–avidin to detect the immunoprecipitated
fusion proteins and the vinculin tail fragment. The proteins
(0.1–0.3 mg/ml in 50 mM NaHCO3 pH 8.3, 20 mM NaCl) were biotiny-
lated essentially as described [34]. Biotinylation did not interfere with
the biological activity of the probes, as judged by their ability to bind
ligands as efficiently as their nonbiotinylated counterparts [34]. Full-
length, purified vinculin, not biotinylated, and its proteolytically derived,
biotinylated tail fragment and the biotinylated proteins (10 pmol,
0.7 µM) were incubated in the presence or absence of PIP2 micelles
(1 nmol, 70 µM) for 30–45 min at 37°C in LP buffer containing 20 mM
β-mercaptoethanol. Samples were supplemented with 2% (w:v) BSA
and incubated with an antibody against PIP2 (DRG Instruments) for 1 h
on ice. Immunocomplexes were precipitated by the addition of protein-
A–Sepharose (Sigma). After another incubation for 1 h on ice, and
15 sec centrifugation at 10,000 × g, pellets were collected and
washed four times with TBST (20 mM Tris HCl pH 7.6, 150 mM NaCl,
0.1% (v:v) Tween-20, 20 mM β-mercaptoethanol) and subjected to
SDS–PAGE. Precipitated recombinant proteins were identified by
incubating the gels with avidin–HRP, followed by enhanced chemi-
luminescence. For the detection of purified vinculin, a vinculin-tail-spe-
cific antibody and a second HRP-coupled antibody were used.
Immunoprecipitation of protein complexes after in situ cross-
linking 
In situ cross-linking was performed as described [48,49]. Briefly,
2.5 × 106 HeLa cells were grown on 10 cm dishes in DMEM with 10%
FCS. They were then washed twice with PBS and incubated at room
temperature for 30 min in 2 ml PBS per dish, containing the membrane-
permeable cross-linker DSP (final concentration 0.5 mM). After two
subsequent washing steps in PBS, excess cross-linker was quenched
with 0.2 M glycine in 2 ml PBS per dish. Finally, the cells were again
washed with PBS and incubated for 30 min at 4°C in 1 ml per dish
RIPA buffer (50 mM Tris, pH 7.2, 1% (v:v) Triton X-100, 0.25% desoxy-
cholate, 1 mM EGTA, 150 mM NaCl, 20 mM glycine, 2.5 mM sodium
azide, 1 µM pepstatin A, 80 µM pefabloc SC, 0.46 µM aprotinin) for
lysis. Control samples, not treated with cross-linker, were obtained by
directly lysing cells in RIPA buffer. Cellular material was then scraped
off the dish with a rubber policeman, homogenized by pipetting and
centrifuged at 15,000 × g for 10 min at 4°C. Monoclonal antibodies
against human vinculin or VASP were added to the supernatants (5 µl
anti-vinculin, 100 µl of a mixture of two monoclonal VASP antibodies,
see below) and the samples were incubated for 16 h at 4°C. Then
50 µl of a 50% slurry of protein-G–Sepharose preblocked with 2%
BSA in RIPA buffer was added to the samples, which were then further
incubated under stirring at 4°C for 1 h. The Sepharose beads were
then collected by centrifugation, washed twice in RIPA buffer and once
with PBS before the samples were boiled in SDS sample buffer includ-
ing 20% β-mercaptoethanol, to cleave the cross-linker. Finally, samples
were analyzed by SDS–PAGE and immunoblotting.
Antibodies
Monoclonal antibodies specific for the vinculin head (15E7) and tail
(4E7) fragments were raised against avian vinculin and characterized in
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our laboratory. A monoclonal antibody against human vinculin was from
BIOMOL. The monoclonal antibodies against human VASP, including
some which were specific for either the EVH1 or EVH2 domains of
VASP, were a kind gift of J. Wehland. Goat serum raised against a
VASP-specific peptide (amino-acid residues 339–357) was from
Santa Cruz Biotechnology. A monoclonal antibody against PIP2 was
from DRG Instruments. Secondary antibodies for immunoblots were
HRP-coupled goat anti-mouse, alkaline-phosphatase-coupled rabbit
anti-mouse, or rabbit anti-goat IgG, respectively, from Sigma. For
immunofluorescence, goat anti-mouse Fab conjugated with FITC
(Dianova) and goat anti-mouse IgG conjugated with TRITC (Sigma)
were used.
Localization of VASP and vinculin in cells. 
Non-confluent cultures of HeLa cells were removed from the dish. Cells
(5 × 105) were reseeded on collagenized glass coverslips and returned
to the incubator for 30–60 min. Cells were then fixed with 3.7%
formaldehyde, extracted in 0.2% Triton X-100 and processed for
double immunofluorescence. They were incubated with the monoclonal
antibody against human vinculin, followed by FITC-conjugated goat
anti-mouse Fab, and subsequently with a monoclonal anti-VASP and
goat anti-mouse IgG conjugated with TRITC. Images were obtained by
using either a conventional light microscope (Zeiss) equipped with epi-
fluorescence and conventional photography, or a confocal laser scan-
ning microscope (Noran Instrument) with the corresponding image
processing equipment.
Supplementary material
A table of the primers used for PCR of vinculin constructs is published
with this paper on the internet.
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